Skip to main content

Envisioning is an emerging technology research institute and advisory.

LinkedInInstagramGitHub

2011 — 2026

research
  • Reports
  • Newsletter
  • Methodology
  • Origins
  • Vocab
services
  • Research Sessions
  • Signals Workspace
  • Bespoke Projects
  • Use Cases
  • Signal Scanfree
  • Readinessfree
impact
  • ANBIMAFuture of Brazilian Capital Markets
  • IEEECharting the Energy Transition
  • Horizon 2045Future of Human and Planetary Security
  • WKOTechnology Scanning for Austria
audiences
  • Innovation
  • Strategy
  • Consultants
  • Foresight
  • Associations
  • Governments
resources
  • Pricing
  • Partners
  • How We Work
  • Data Visualization
  • Multi-Model Method
  • FAQ
  • Security & Privacy
about
  • Manifesto
  • Community
  • Events
  • Support
  • Contact
  • Login
ResearchServicesPricingPartnersAbout
ResearchServicesPricingPartnersAbout
  1. Home
  2. Research
  3. Helix
  4. Normothermic Organ Perfusion Bioreactors

Normothermic Organ Perfusion Bioreactors

Ex vivo life-support systems that repair and rejuvenate organs before transplantation.
Back to HelixView interactive version

Normothermic organ perfusion bioreactors are ex vivo life-support systems that keep donor organs metabolically active outside the body using oxygenated, nutrient-rich perfusate (fluid) at body temperature, maintaining organ function and viability during transport and storage. Emerging protocols are layering gene therapy, cell therapy, and pharmacological treatments onto these platforms to actively repair, rejuvenate, or improve aged or marginal organs prior to transplantation, potentially expanding the pool of usable donor organs and improving transplant outcomes, hinting at future capabilities for whole-organ repair and rejuvenation for longevity medicine.

This innovation addresses the critical shortage of donor organs and the problem of organ quality, where many potential donor organs are discarded because they're considered too old or damaged. By maintaining organs in a functional state outside the body and applying therapeutic interventions, these systems can improve organ quality, extend preservation times, and potentially repair damage, making more organs suitable for transplantation. Companies like OrganOx, TransMedics, and research institutions are developing these technologies.

The technology is particularly significant for addressing the organ shortage crisis, where thousands of people die waiting for transplants each year. As the technology improves and therapeutic capabilities expand, it could dramatically increase the number of usable organs and improve transplant outcomes. However, ensuring organ viability, developing effective repair protocols, and managing system complexity remain challenges. The technology represents an important advance in organ preservation and could enable new approaches to organ repair, but requires continued development to achieve its full potential. Success could transform transplantation medicine by expanding the organ supply and improving outcomes, potentially saving many lives and serving as a model for organ repair and rejuvenation approaches.

TRL
7/9Operational
Impact
4/5
Investment
4/5
Category
Hardware

Related Organizations

OrganOx logo
OrganOx

United Kingdom · Company

95%

Creators of the metra system, which preserves donor livers at body temperature for up to 24 hours prior to transplant.

Developer
TransMedics logo
TransMedics

United States · Company

95%

Developer of the Organ Care System (OCS), a portable normothermic perfusion platform for heart, lung, and liver transplantation.

Developer
Bridge to Life

United States · Company

85%

Develops organ preservation solutions and the VitaSmart machine perfusion system.

Developer
Organ Assist

Netherlands · Company

85%

Develops perfusion systems for liver (Liver Assist) and kidney (Kidney Assist), focusing on oxygenated perfusion.

Developer
University of Zurich logo
University of Zurich

Switzerland · University

85%

Home to the Robotics and Perception Group (RPG).

Researcher
Ebers Medical

Spain · Company

80%

Spanish biotech developing the ARK normothermic kidney perfusion system.

Developer
Vanderbilt University Medical Center logo
Vanderbilt University Medical Center

United States · University

80%

Conducts advanced research on cross-circulation platforms to rehabilitate donor lungs and livers ex vivo.

Researcher
Institut de Recerca Sant Pau

Spain · Research Lab

70%

Barcelona-based research institute conducting clinical trials on normothermic regional perfusion.

Researcher

Supporting Evidence

Evidence data is not available for this technology yet.

Same technology in other hubs

Epoch
Epoch
Whole-Organ Regeneration Bioreactors

Perfusion systems that repair and rejuvenate donor organs outside the body for transplantation

Connections

Hardware
Hardware
Organ-on-Chip & Multi-Organ Microphysiological Systems

Microfluidic platforms simulating aging and rejuvenation pathways.

TRL
6/9
Impact
4/5
Investment
3/5
Hardware
Hardware
Organ Bioprinting Systems

Large-format bioprinters fabricating perfusable organ scaffolds.

TRL
4/9
Impact
5/5
Investment
5/5
Hardware
Hardware
3D-Bioprinted Vascularized Tissue Constructs

Printers capable of generating functional capillary networks within lab-grown organs.

TRL
4/9
Impact
5/5
Investment
4/5
Applications
Applications
Female Reproductive Longevity Interventions

Ovarian reserve preservation and regeneration for extended healthspan.

TRL
3/9
Impact
4/5
Investment
3/5
Hardware
Hardware
Cryopreservation Automation

Robotic vitrification systems standardizing cell and tissue banking.

TRL
6/9
Impact
4/5
Investment
4/5
Applications
Applications
Systemic Milieu Reset Protocols

Plasmapheresis and plasma-mimetic therapies to rebalance pro- and anti-aging factors.

TRL
4/9
Impact
4/5
Investment
4/5

Book a research session

Bring this signal into a focused decision sprint with analyst-led framing and synthesis.
Research Sessions